iCAP Project targets world-first continuous pDNA production

Recombinant proteins and genetics specialist CDMO enGenes Biotech has embarked on a potentially transformational project to create a platform for continuous automated production of plasmid DNA (pDNA).

The iCAP Project (Integrated Continuous and Automated Platform for Plasmid Production) is partly consequent from the success of the ECOnti collaboration for continuous protein production that united enGenes with development partners novasign® and Qubicon® AG to pioneer continuous production processes for proteins.

Transformational project

The goal of iCAP is to establish a scalable, intelligent pilot system that can deliver consistent, cost-effective, and eco-friendly pDNA for cell and gene therapy, viral vectors, and mRNA vaccines. If successful, it will create the first single fully continuous low-cost pDNA production center to be found anywhere in the world.

This would be transformational for the pharma and biotech industries that currently face challenges with current pDNA production methods that are inefficient and costly, relying on discontinuous batch and fed-batch processes. Cost-effective and efficient continuous production of pDNA would enable a significant reduction in the manufacturing costs of the novel drugs required for medical progress.

Read the full article here: https://www.pharmaceutical-networking.com/icap-project-targets-world-first-continuous-pdna-production/